Compare UUUU & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UUUU | GKOS |
|---|---|---|
| Founded | 1987 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 6.9B |
| IPO Year | 2006 | 2015 |
| Metric | UUUU | GKOS |
|---|---|---|
| Price | $20.07 | $103.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 14 |
| Target Price | $19.92 | ★ $133.07 |
| AVG Volume (30 Days) | ★ 9.0M | 679.7K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | $65,922,000.00 | ★ $507,442,000.00 |
| Revenue This Year | $113.24 | $23.39 |
| Revenue Next Year | $36.77 | $27.46 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 32.33 |
| 52 Week Low | $3.20 | $73.16 |
| 52 Week High | $27.90 | $130.23 |
| Indicator | UUUU | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 46.04 | 35.28 |
| Support Level | $19.34 | $81.54 |
| Resistance Level | $23.61 | $106.52 |
| Average True Range (ATR) | 1.73 | 3.58 |
| MACD | -0.30 | -1.81 |
| Stochastic Oscillator | 25.96 | 14.28 |
Energy Fuels Inc is a United States-based critical minerals company. The Company mines uranium and produces natural uranium concentrates that are sold to nuclear utilities for the production of carbon-free nuclear energy. It holds two of America's key uranium production centers: The White Mesa Mill in Utah, and the Nichols Ranch ISR Facility in Wyoming. It has three reportable segments based on its operations and financial information; Uranium, HMS, and REE.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.